詳細検索

詳細検索

お問い合わせ

Osteoporosis Drugs Market Report by Product Type (Bisphosphonates, Calcitonin, Rank Ligand Inhibitor, Parathyroid Hormone Therapy (PTH), Selective Estrogen Receptor Modulators (SERMs), Sclerostin Inhibitor, and Others), Route of Administration (Oral, Injectable, and Others), and Region 2026-2034

Osteoporosis Drugs Market Report by Product Type (Bisphosphonates, Calcitonin, Rank Ligand Inhibitor, Parathyroid Hormone Therapy (PTH), Selective Estrogen Receptor Modulators (SERMs), Sclerostin Inhibitor, and Others), Route of Administration (Oral, Injectable, and Others), and Region 2026-2034


The global osteoporosis drugs market size reached USD 18.0 Billion in 2025. Looking forward, IMARC Group expects the market to reach USD 25.4 Billion by 2034, exhibiting a growth rate (CAGR) of 3.8... もっと見る

 

 

出版社
IMARC Services Private Limited.
アイマークサービス
出版年月
2026年5月1日
電子版価格
US$3,999
シングルユーザーライセンス(印刷不可)
ライセンス・価格情報/注文方法はこちら
納期
3-5営業日以内
ページ数
150
言語
英語

英語原文をAIを使って翻訳しています。


 

Summary

The global osteoporosis drugs market size reached USD 18.0 Billion in 2025. Looking forward, IMARC Group expects the market to reach USD 25.4 Billion by 2034, exhibiting a growth rate (CAGR) of 3.82% during 2026-2034.

Osteoporosis is a disease that causes deterioration of bone tissues and strength. It is diagnosed by performing different scans, such as X-ray, computed tomography (CT) and magnetic resonance imaging (MRI). Various drugs are currently available in different formulations, ranging from regular tablets to intravenous (IV) infusions, for alleviating the symptoms of osteoporosis. These drugs help restore the balance of resorption and formation, repair microscopic defects in bones, reduce the risk of fractures and improve the overall muscle strength of the patients.

The growing prevalence of osteoporosis on account of sedentary lifestyles, excessive consumption of alcohol, and rising utilization of tobacco represent the key factors bolstering the growth of the market. The increasing number of individuals who have celiac disease, kidney or liver disease, cancer, lupus, multiple myeloma and rheumatoid arthritis is further accelerating the market growth. Moreover, bone mass loss increases with age, which raises the risk of developing osteoporosis among older people. Consequently, the rising geriatric population is positively influencing the demand for osteoporosis drugs worldwide. Furthermore, several governing authorities are developing novel therapeutics, which is contributing to the market growth. For instance, the US Food and Drug Administration (FDA) has approved novel osteoporosis drugs for postmenopausal women who are at a high risk of fractures or are intolerant to other osteoporosis therapies. Besides this, a wide range of drugs in late-stage clinical trials is anticipated to propel the market growth in the coming years.

KEY MARKET SEGMENTATION:

IMARC Group provides an analysis of the key trends in each sub-segment of the global osteoporosis drugs market report, along with forecasts at the global, regional and country level from 2026-2034. Our report has categorized the market based on product type and route of administration.

Breakup by Product Type:

? Bisphosphonates

? Calcitonin

? Rank Ligand Inhibitor

? Parathyroid Hormone Therapy (PTH)

? Selective Estrogen Receptor Modulators (SERMs)

? Sclerostin Inhibitor

? Others

Breakup by Route of Administration:

? Oral

? Injectable

? Others

Breakup by Region:

? North America

o United States

o Canada

? Asia-Pacific

o China

o Japan

o India

o South Korea

o Australia

o Indonesia

o Others

? Europe

o Germany

o France

o United Kingdom

o Italy

o Spain

o Russia

o Others

? Latin America

o Brazil

o Mexico

o Others

? Middle East and Africa

COMPETITIVE LANDSCAPE:

The competitive landscape of the industry has also been examined along with the profiles of the key players being Amgen Inc., Eli Lilly and Company, F. Hoffmann-La Roche AG, GlaxoSmithKline Plc, Merck & Co. Inc., Novartis AG, Pfizer Inc., Radius Health Inc., Teva Pharmaceutical Industries Ltd. and UCB S.A.

Key Questions Answered in This Report
1. How big is the global osteoporosis drugs market?
2. What is the expected growth rate of the global osteoporosis drugs market during 2026-2034?
3. What are the key factors driving the global osteoporosis drugs market?
4. What has been the impact of COVID-19 on the global osteoporosis drugs market?
5. What is the breakup of the global osteoporosis drugs market based on the product type?
6. What is the breakup of the global osteoporosis drugs market based on the route of administration?
7. What are the key regions in the global osteoporosis drugs market?
8. Who are the key players/companies in the global osteoporosis drugs market?

ページTOPに戻る


Table of Contents

1 Preface
2 Scope and Methodology
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 Executive Summary
4 Introduction
4.1 Overview
4.2 Key Industry Trends
5 Global Osteoporosis Drugs Market
5.1 Market Overview
5.2 Market Performance
5.3 Impact of COVID-19
5.4 Market Forecast
6 Market Breakup by Product Type
6.1 Bisphosphonates
6.1.1 Market Trends
6.1.2 Market Forecast
6.2 Calcitonin
6.2.1 Market Trends
6.2.2 Market Forecast
6.3 Rank Ligand Inhibitor
6.3.1 Market Trends
6.3.2 Market Forecast
6.4 Parathyroid Hormone Therapy (PTH)
6.4.1 Market Trends
6.4.2 Market Forecast
6.5 Selective Estrogen Receptor Modulators (SERMs)
6.5.1 Market Trends
6.5.2 Market Forecast
6.6 Sclerostin Inhibitor
6.6.1 Market Trends
6.6.2 Market Forecast
6.7 Others
6.7.1 Market Trends
6.7.2 Market Forecast
7 Market Breakup by Route of Administration
7.1 Oral
7.1.1 Market Trends
7.1.2 Market Forecast
7.2 Injectable
7.2.1 Market Trends
7.2.2 Market Forecast
7.3 Others
7.3.1 Market Trends
7.3.2 Market Forecast
8 Market Breakup by Region
8.1 North America
8.1.1 United States
8.1.1.1 Market Trends
8.1.1.2 Market Forecast
8.1.2 Canada
8.1.2.1 Market Trends
8.1.2.2 Market Forecast
8.2 Asia-Pacific
8.2.1 China
8.2.1.1 Market Trends
8.2.1.2 Market Forecast
8.2.2 Japan
8.2.2.1 Market Trends
8.2.2.2 Market Forecast
8.2.3 India
8.2.3.1 Market Trends
8.2.3.2 Market Forecast
8.2.4 South Korea
8.2.4.1 Market Trends
8.2.4.2 Market Forecast
8.2.5 Australia
8.2.5.1 Market Trends
8.2.5.2 Market Forecast
8.2.6 Indonesia
8.2.6.1 Market Trends
8.2.6.2 Market Forecast
8.2.7 Others
8.2.7.1 Market Trends
8.2.7.2 Market Forecast
8.3 Europe
8.3.1 Germany
8.3.1.1 Market Trends
8.3.1.2 Market Forecast
8.3.2 France
8.3.2.1 Market Trends
8.3.2.2 Market Forecast
8.3.3 United Kingdom
8.3.3.1 Market Trends
8.3.3.2 Market Forecast
8.3.4 Italy
8.3.4.1 Market Trends
8.3.4.2 Market Forecast
8.3.5 Spain
8.3.5.1 Market Trends
8.3.5.2 Market Forecast
8.3.6 Russia
8.3.6.1 Market Trends
8.3.6.2 Market Forecast
8.3.7 Others
8.3.7.1 Market Trends
8.3.7.2 Market Forecast
8.4 Latin America
8.4.1 Brazil
8.4.1.1 Market Trends
8.4.1.2 Market Forecast
8.4.2 Mexico
8.4.2.1 Market Trends
8.4.2.2 Market Forecast
8.4.3 Others
8.4.3.1 Market Trends
8.4.3.2 Market Forecast
8.5 Middle East and Africa
8.5.1 Market Trends
8.5.2 Market Breakup by Country
8.5.3 Market Forecast
9 SWOT Analysis
9.1 Overview
9.2 Strengths
9.3 Weaknesses
9.4 Opportunities
9.5 Threats
10 Value Chain Analysis
11 Porters Five Forces Analysis
11.1 Overview
11.2 Bargaining Power of Buyers
11.3 Bargaining Power of Suppliers
11.4 Degree of Competition
11.5 Threat of New Entrants
11.6 Threat of Substitutes
12 Price Analysis
13 Competitive Landscape
13.1 Market Structure
13.2 Key Players
13.3 Profiles of Key Players
13.3.1 Amgen Inc.
13.3.1.1 Company Overview
13.3.1.2 Product Portfolio
13.3.1.3 Financials
13.3.1.4 SWOT Analysis
13.3.2 Eli Lilly and Company
13.3.2.1 Company Overview
13.3.2.2 Product Portfolio
13.3.2.3 Financials
13.3.2.4 SWOT Analysis
13.3.3 F. Hoffmann-La Roche AG
13.3.3.1 Company Overview
13.3.3.2 Product Portfolio
13.3.3.3 SWOT Analysis
13.3.4 GlaxoSmithKline Plc
13.3.4.1 Company Overview
13.3.4.2 Product Portfolio
13.3.4.3 Financials
13.3.4.4 SWOT Analysis
13.3.5 Merck & Co. Inc.
13.3.5.1 Company Overview
13.3.5.2 Product Portfolio
13.3.5.3 Financials
13.3.5.4 SWOT Analysis
13.3.6 Novartis AG
13.3.6.1 Company Overview
13.3.6.2 Product Portfolio
13.3.6.3 Financials
13.3.6.4 SWOT Analysis
13.3.7 Pfizer Inc.
13.3.7.1 Company Overview
13.3.7.2 Product Portfolio
13.3.7.3 Financials
13.3.7.4 SWOT Analysis
13.3.8 Radius Health Inc.
13.3.8.1 Company Overview
13.3.8.2 Product Portfolio
13.3.8.3 Financials
13.3.9 Teva Pharmaceutical Industries Ltd.
13.3.9.1 Company Overview
13.3.9.2 Product Portfolio
13.3.9.3 Financials
13.3.9.4 SWOT Analysis
13.3.10 UCB S.A.
13.3.10.1 Company Overview
13.3.10.2 Product Portfolio
13.3.10.3 Financials
13.3.10.4 SWOT Analysis

ページTOPに戻る



List of Tables/Graphs

List of Figures
Figure 1: Global: Osteoporosis Drugs Market: Major Drivers and Challenges
Figure 2: Global: Osteoporosis Drugs Market: Sales Value (in Billion USD), 2020-2025
Figure 3: Global: Osteoporosis Drugs Market: Breakup by Product Type (in %), 2025
Figure 4: Global: Osteoporosis Drugs Market: Breakup by Route of Administration (in %), 2025
Figure 5: Global: Osteoporosis Drugs Market: Breakup by Region (in %), 2025
Figure 6: Global: Osteoporosis Drugs Market Forecast: Sales Value (in Billion USD), 2026-2034
Figure 7: Global: Osteoporosis Drugs (Bisphosphonates) Market: Sales Value (in Million USD), 2020 & 2025
Figure 8: Global: Osteoporosis Drugs (Bisphosphonates) Market Forecast: Sales Value (in Million USD), 2026-2034
Figure 9: Global: Osteoporosis Drugs (Calcitonin) Market: Sales Value (in Million USD), 2020 & 2025
Figure 10: Global: Osteoporosis Drugs (Calcitonin) Market Forecast: Sales Value (in Million USD), 2026-2034
Figure 11: Global: Osteoporosis Drugs (Rank Ligand Inhibitor) Market: Sales Value (in Million USD), 2020 & 2025
Figure 12: Global: Osteoporosis Drugs (Rank Ligand Inhibitor) Market Forecast: Sales Value (in Million USD), 2026-2034
Figure 13: Global: Osteoporosis Drugs (Parathyroid Hormone Therapy- PTH) Market: Sales Value (in Million USD), 2020 & 2025
Figure 14: Global: Osteoporosis Drugs (Parathyroid Hormone Therapy- PTH) Market Forecast: Sales Value (in Million USD), 2026-2034
Figure 15: Global: Osteoporosis Drugs (Selective Estrogen Receptor Modulators- SERMs) Market: Sales Value (in Million USD), 2020 & 2025
Figure 16: Global: Osteoporosis Drugs (Selective Estrogen Receptor Modulators- SERMs) Market Forecast: Sales Value (in Million USD), 2026-2034
Figure 17: Global: Osteoporosis Drugs (Sclerostin Inhibitor) Market: Sales Value (in Million USD), 2020 & 2025
Figure 18: Global: Osteoporosis Drugs (Sclerostin Inhibitor) Market Forecast: Sales Value (in Million USD), 2026-2034
Figure 19: Global: Osteoporosis Drugs (Others) Market: Sales Value (in Million USD), 2020 & 2025
Figure 20: Global: Osteoporosis Drugs (Others) Market Forecast: Sales Value (in Million USD), 2026-2034
Figure 21: Global: Osteoporosis Drugs (Oral) Market: Sales Value (in Million USD), 2020 & 2025
Figure 22: Global: Osteoporosis Drugs (Oral) Market Forecast: Sales Value (in Million USD), 2026-2034
Figure 23: Global: Osteoporosis Drugs (Injectable) Market: Sales Value (in Million USD), 2020 & 2025
Figure 24: Global: Osteoporosis Drugs (Injectable) Market Forecast: Sales Value (in Million USD), 2026-2034
Figure 25: Global: Osteoporosis Drugs (Others) Market: Sales Value (in Million USD), 2020 & 2025
Figure 26: Global: Osteoporosis Drugs (Others) Market Forecast: Sales Value (in Million USD), 2026-2034
Figure 27: North America: Osteoporosis Drugs Market: Sales Value (in Million USD), 2020 & 2025
Figure 28: North America: Osteoporosis Drugs Market Forecast: Sales Value (in Million USD), 2026-2034
Figure 29: United States: Osteoporosis Drugs Market: Sales Value (in Million USD), 2020 & 2025
Figure 30: United States: Osteoporosis Drugs Market Forecast: Sales Value (in Million USD), 2026-2034
Figure 31: Canada: Osteoporosis Drugs Market: Sales Value (in Million USD), 2020 & 2025
Figure 32: Canada: Osteoporosis Drugs Market Forecast: Sales Value (in Million USD), 2026-2034
Figure 33: Asia-Pacific: Osteoporosis Drugs Market: Sales Value (in Million USD), 2020 & 2025
Figure 34: Asia-Pacific: Osteoporosis Drugs Market Forecast: Sales Value (in Million USD), 2026-2034
Figure 35: China: Osteoporosis Drugs Market: Sales Value (in Million USD), 2020 & 2025
Figure 36: China: Osteoporosis Drugs Market Forecast: Sales Value (in Million USD), 2026-2034
Figure 37: Japan: Osteoporosis Drugs Market: Sales Value (in Million USD), 2020 & 2025
Figure 38: Japan: Osteoporosis Drugs Market Forecast: Sales Value (in Million USD), 2026-2034
Figure 39: India: Osteoporosis Drugs Market: Sales Value (in Million USD), 2020 & 2025
Figure 40: India: Osteoporosis Drugs Market Forecast: Sales Value (in Million USD), 2026-2034
Figure 41: South Korea: Osteoporosis Drugs Market: Sales Value (in Million USD), 2020 & 2025
Figure 42: South Korea: Osteoporosis Drugs Market Forecast: Sales Value (in Million USD), 2026-2034
Figure 43: Australia: Osteoporosis Drugs Market: Sales Value (in Million USD), 2020 & 2025
Figure 44: Australia: Osteoporosis Drugs Market Forecast: Sales Value (in Million USD), 2026-2034
Figure 45: Indonesia: Osteoporosis Drugs Market: Sales Value (in Million USD), 2020 & 2025
Figure 46: Indonesia: Osteoporosis Drugs Market Forecast: Sales Value (in Million USD), 2026-2034
Figure 47: Others: Osteoporosis Drugs Market: Sales Value (in Million USD), 2020 & 2025
Figure 48: Others: Osteoporosis Drugs Market Forecast: Sales Value (in Million USD), 2026-2034
Figure 49: Europe: Osteoporosis Drugs Market: Sales Value (in Million USD), 2020 & 2025
Figure 50: Europe: Osteoporosis Drugs Market Forecast: Sales Value (in Million USD), 2026-2034
Figure 51: Germany: Osteoporosis Drugs Market: Sales Value (in Million USD), 2020 & 2025
Figure 52: Germany: Osteoporosis Drugs Market Forecast: Sales Value (in Million USD), 2026-2034
Figure 53: France: Osteoporosis Drugs Market: Sales Value (in Million USD), 2020 & 2025
Figure 54: France: Osteoporosis Drugs Market Forecast: Sales Value (in Million USD), 2026-2034
Figure 55: United Kingdom: Osteoporosis Drugs Market: Sales Value (in Million USD), 2020 & 2025
Figure 56: United Kingdom: Osteoporosis Drugs Market Forecast: Sales Value (in Million USD), 2026-2034
Figure 57: Italy: Osteoporosis Drugs Market: Sales Value (in Million USD), 2020 & 2025
Figure 58: Italy: Osteoporosis Drugs Market Forecast: Sales Value (in Million USD), 2026-2034
Figure 59: Spain: Osteoporosis Drugs Market: Sales Value (in Million USD), 2020 & 2025
Figure 60: Spain: Osteoporosis Drugs Market Forecast: Sales Value (in Million USD), 2026-2034
Figure 61: Russia: Osteoporosis Drugs Market: Sales Value (in Million USD), 2020 & 2025
Figure 62: Russia: Osteoporosis Drugs Market Forecast: Sales Value (in Million USD), 2026-2034
Figure 63: Others: Osteoporosis Drugs Market: Sales Value (in Million USD), 2020 & 2025
Figure 64: Others: Osteoporosis Drugs Market Forecast: Sales Value (in Million USD), 2026-2034
Figure 65: Latin America: Osteoporosis Drugs Market: Sales Value (in Million USD), 2020 & 2025
Figure 66: Latin America: Osteoporosis Drugs Market Forecast: Sales Value (in Million USD), 2026-2034
Figure 67: Brazil: Osteoporosis Drugs Market: Sales Value (in Million USD), 2020 & 2025
Figure 68: Brazil: Osteoporosis Drugs Market Forecast: Sales Value (in Million USD), 2026-2034
Figure 69: Mexico: Osteoporosis Drugs Market: Sales Value (in Million USD), 2020 & 2025
Figure 70: Mexico: Osteoporosis Drugs Market Forecast: Sales Value (in Million USD), 2026-2034
Figure 71: Others: Osteoporosis Drugs Market: Sales Value (in Million USD), 2020 & 2025
Figure 72: Others: Osteoporosis Drugs Market Forecast: Sales Value (in Million USD), 2026-2034
Figure 73: Middle East and Africa: Osteoporosis Drugs Market: Sales Value (in Million USD), 2020 & 2025
Figure 74: Middle East and Africa: Osteoporosis Drugs Market Forecast: Sales Value (in Million USD), 2026-2034
Figure 75: Middle East and Africa: Osteoporosis Drugs Market: Breakup by Country (in %), 2025
Figure 76: Global: Osteoporosis Drugs Industry: SWOT Analysis
Figure 77: Global: Osteoporosis Drugs Industry: Value Chain Analysis
Figure 78: Global: Osteoporosis Drugs Industry: Porter's Five Forces Analysis

List of Tables
Table 1: Global: Osteoporosis Drugs Market: Key Industry Highlights, 2025 and 2034
Table 2: Global: Osteoporosis Drugs Market Forecast: Breakup by Product Type (in Million USD), 2026-2034
Table 3: Global: Osteoporosis Drugs Market Forecast: Breakup by Route of Administration (in Million USD), 2026-2034
Table 4: Global: Osteoporosis Drugs Market Forecast: Breakup by Region (in Million USD), 2026-2034
Table 5: Global: Osteoporosis Drugs Market: Competitive Structure
Table 6: Global: Osteoporosis Drugs Market: Key Players

 

ページTOPに戻る

ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

webからのご注文・お問合せはこちらのフォームから承ります

本レポートと同分野(医療)の最新刊レポート

IMARC Services Private Limited.社の 医療分野 での最新刊レポート

本レポートと同じKEY WORD(osteoporosis drugs)の最新刊レポート


よくあるご質問


IMARC Services Private Limited.社はどのような調査会社ですか?


インドに調査拠点を持つ調査会社。幅広い分野をカバーしていますがケミカルに特に焦点を当てています。 もっと見る


調査レポートの納品までの日数はどの程度ですか?


在庫のあるものは速納となりますが、平均的には 3-4日と見て下さい。
但し、一部の調査レポートでは、発注を受けた段階で内容更新をして納品をする場合もあります。
発注をする前のお問合せをお願いします。


注文の手続きはどのようになっていますか?


1)お客様からの御問い合わせをいただきます。
2)見積書やサンプルの提示をいたします。
3)お客様指定、もしくは弊社の発注書をメール添付にて発送してください。
4)データリソース社からレポート発行元の調査会社へ納品手配します。
5) 調査会社からお客様へ納品されます。最近は、pdfにてのメール納品が大半です。


お支払方法の方法はどのようになっていますか?


納品と同時にデータリソース社よりお客様へ請求書(必要に応じて納品書も)を発送いたします。
お客様よりデータリソース社へ(通常は円払い)の御振り込みをお願いします。
請求書は、納品日の日付で発行しますので、翌月最終営業日までの当社指定口座への振込みをお願いします。振込み手数料は御社負担にてお願いします。
お客様の御支払い条件が60日以上の場合は御相談ください。
尚、初めてのお取引先や個人の場合、前払いをお願いすることもあります。ご了承のほど、お願いします。


データリソース社はどのような会社ですか?


当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
世界各国の「市場・技術・法規制などの」実情を調査・収集される時には、データリソース社にご相談ください。
お客様の御要望にあったデータや情報を抽出する為のレポート紹介や調査のアドバイスも致します。


詳細検索

このレポートへのお問合せ

03-3582-2531

電話お問合せもお気軽に

 

 

2026/05/27 10:27

160.33 円

186.90 円

218.43 円

ページTOPに戻る